Project members

The challenge is to be selective, to avoid global immune suppression; and non-invasive, to intervene as early as possible in children at risk of developing T1D. We have devised a novel oral vaccine using Fc-fused preproinsulin (PPI-Fc) that meets these criteria, and we are currently exploring its therapeutic efficacy for T1D prevention (Corcos et al. Front Immunol 2021).